This comprehensive book explores the groundbreaking research and development of GLP-1 based therapies for diabetes and weight management.

It dives into the origins of GLP-1 research in the 1980s, highlighting key milestones such as the advent of exenatide, liraglutide, and semaglutide.

The book discusses molecular design challenges, formulation innovations, and the clinical trial breakthroughs that have transformed treatment approaches.

It examines the biology and receptor distribution of GLP-1 and GIP, their effects on insulin secretion, gastric emptying, and satiety, as well as their broader impacts on metabolism, cardiovascular health, and chronic conditions like NAFLD and PCOS.

Special attention is given to the development of combination therapies like tirzepatide, head-to-head studies comparing therapies, and emerging uses beyond diabetes and obesity.

The book also addresses regulatory pathways, off-label trends, side effects, dosing strategies, and societal implications, including market rollout, patient responses, and the influence of social media and influencers.

It provides insights into personalized medicine, future innovations such as oral and small-molecule mimetics, and the global landscape of GLP-1 therapies.

Aimed at clinicians, researchers, policymakers, and curious readers alike, this book offers an in-depth understanding of one of the most significant advances in metabolic medicine of the modern era.